肝癌多药耐药相关P-糖蛋白异常表达及其临床价值分析

Abnormal expression of multi-drug resistance-related P-glycoprotein and its clinical values in tissues of heptocellular carcinoma

目的 :研究分析了肝细胞性肝癌(hepatocellular carcinoma,HCC)组织P-糖蛋白(P-glycoprotein,P-gp)表达、临床病理学特征及对患者生存的影响。方法:采用组织芯片及免疫组织化学法检测75份人HCC癌组织及配对癌周组织P-gp表达。结果:HCC癌组织P-gp表达主要定位于细胞膜和细胞浆,其阳性表达率为70.67%显著高于(χ2=27.312,P<0.001)自身对照的癌周组织的28.00%;癌组织P-gp过表达与淋巴结转移(χ2=4.342,P=0.037),TNM分期(χ2=6.079,P=0.014)和5年生存率(χ2=7.205,P=0.007)显著相关;而与患者年龄、性别、甲胎蛋白水平、门静脉侵犯、乙型肝炎病毒感染、肝硬化、分化程度、肿瘤大小及Child分级等未见明显相关。结论:肝癌多药耐药形成过程中MDR1/P-gp异常表达,与肝癌细胞多药耐药形成相关。

Objective： To investigate the expression of P-gp in HCC tissues, its correlations with the clinicopathological features, and patient＇s survival to observe the effects on reversing MDR of HCC. Methods： The P-gp expressions were detected in 75 HCC and their para-cancerous tissues by immunohistochemistry. Results： The positive expression of hepatic P-gp was mainly localized in cell membrane and cytoplasm. The incidence of P-gp expression（70.67%） in the HCC tissues was significantly higher（ χ2=27.312, P〈0.001） than that in the self-control para-cancerous tissues（28.00%）. The over-expression of P-gp in the HCC tissues was closely related to lymph node metastasis（ χ2=4.342, P=0.037）, TNM stage（ χ2=6.079, P=0.014）,and 5-year survival（ χ2=7.205, P=0.007）, and not to age, gender, AFP, portal vein invasion, hepatitis B virus infection, liver cirrhosis,differentiation degree, tumor size, and Child classification. Conclusion： The present data suggested that the abnormal expression of MDR1/P-gp in HCC was related to MDR information.